Showing 1 - 12 results of 12 for search 'Sebastiano Buti', query time: 0.03s
Refine Results
-
1
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau” by Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Pasquale Rescigno, Giuseppe Luigi Banna, Sebastiano Buti
Published 2024-12-01Get full text
Article -
2
Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer an... by Tappei Takada, Yukari Uemura, Haruki Kume, Sebastiano Buti, Satoru Taguchi, Taketo Kawai, Katsuhiko Nara, Takehito Yamamoto
Published 2024-03-01Get full text
Article -
3
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma by Michele Maffezzoli MD, Alessio Signori MD, Davide Campobasso MD, Giulia Claire Giudice MD, Nicola Simoni MD, Massimo De Filippo MD, Enrico Maria Silini MD, Sebastiano Buti MD, PhD
Published 2025-03-01Get full text
Article -
4
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab by Giulia Claire Giudice, Sara Elena Rebuzzi, Giulia Mazzaschi, Federica Pecci, Michele Maffezzoli, Alessandro Acunzo, Letizia Gnetti, Enrico Maria Silini, Giuseppe Caruso, Elena Rapacchi, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna, Sebastiano Buti
Published 2025-01-01Get full text
Article -
5
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection... by Ilaria Gandolfini, Martina Manini, Giuseppe Daniele Benigno, Micaela Gentile, Alessandra Palmisano, Danio Somenzi, Letizia Gnetti, Marco Delsante, Benedetta Mordà, Marta D’Angelo, Daniel Salvetti, Enrico Fiaccadori, Enrico Fiaccadori, Sebastiano Buti, Umberto Maggiore, Umberto Maggiore
Published 2025-03-01Get full text
Article -
6
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study by Maria T. Bourlon, Maria T. Bourlon, Luca Galli, Enrique Grande, Se Hoon Park, Bohuslav Melichar, Timothy J. Schieber, Maria José Juan-Fita, Yüksel Ürün, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Ugo De Giorgi, Jakub Kucharz, Esther Pérez Calabuig, Vincenza Conteduca, Tarek Taha, Tarek Taha, Pasquale Rescigno, Hussam Abu-Sini, Gian Paolo Spinelli, Ray Manneh Kopp, Alessia Salfi, Dipen Bhuva, Paola Valdez-Sandoval, Sofia Mendez-Bribiesca, Ondrej Fiala, Ondrej Fiala, Sebastiano Buti, Sebastiano Buti, Fernando Sabino Marques Monteiro, Fernando Sabino Marques Monteiro, Aristotelis Bamias, Marwan Ghosn, Francesco Massari, Francesco Massari, Jawaher Ansari, Matteo Santoni
Published 2025-07-01Get full text
Article -
7
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience by Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park, Maria T. Bourlon, Enrique Grande, Francesco Massari, Johannes Landmesser, Alexandr Poprach, Hideki Takeshita, Giandomenico Roviello, Zin W. Myint, Lazar Popovic, Andrey Soares, Halima Abahssain, Patrizia Giannatempo, Javier Molina‐Cerrillo, Lorena Incorvaia, Samer Salah, Annalisa Zeppellini, Fernando Sabino Marques Monteiro, Camillo Porta, Shilpa Gupta, Matteo Santoni
Published 2025-02-01Get full text
Article -
8
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy:... by Mimma Rizzo, Andrey Soares, Shilpa Gupta, Fabio Calabrò, Hideki Takeshita, Maria Teresa Bourlon, Se Hoon Park, Patrizia Giannatempo, Zin War Myint, Thomas Büttner, Enrique Grande, Ondrej Fiala, Daniele Santini, Aristotelis Bamias, Roubini Zakopoulou, Sebastiano Buti, Ravindran Kanesvaran, Pasquale Rescigno, Javier Molina-Cerrillo, Ilana Epstein, Fernando Sabino Marques Monteiro, Francesco Massari, Camillo Porta, Joaquin Bellmunt, Matteo Santoni
Published 2025-07-01Get full text
Article -
9
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study by Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, Linda Cerbone, Ondrej Fiala, Giuseppe Fornarini, Fernando Sabino Marques Monteiro, Carlo Cattrini, Johannes Landmesser, Carlo Messina, Anca Zgura, Sara Elena Rebuzzi, Andrey Soares, Francesco Carrozza, Jawaher Ansari, Francesco Grillone, Zsófia Küronya, Lorena Incorvaia, Dipen Bhuva, Cinzia Ortega, Cecilia Nasso, Ravindran Kanesvaran, Ilaria Zampiva, Camillo Porta, Sebastiano Buti, Matteo Santoni
Published 2025-01-01Get full text
Article -
10
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab by Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia, María Natalia Gandur Quiroga, Elaine Lam, Deniz Tural, Lazar Popovic, Saul Campos-Gomez, Paolo Andrea Zucali, Augusto Mota, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Halima Abahssain, Andrea Benedetto Galosi, Giuseppe Badalamenti, Jindrich Kopecky, Aristotelis Bamias, Johannes Landmesser, Jawaher Ansari, Fabio Calabrò, Francesco Massari, Sebastiano Buti, Joaquim Bellmunt, Matteo Santoni
Published 2025-03-01Get full text
Article -
11
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study by Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W. Myint, Giuseppe Fornarini, Thomas Buttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomas Buchler, Hana Studentova, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni
Published 2025-05-01Get full text
Article -
12
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) by Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W. Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner, Martin Pichler, Umberto Basso, Jindrich Kopecky, Maria T. Bourlon, Linda Cerbone, Tomas Buchler, Alvaro Pinto, Alfonso Gómez de Liaño, Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari
Published 2025-05-01Get full text
Article